Patents Assigned to Merck Sharp & Dohme
  • Patent number: 5475008
    Abstract: A class of 2(1H)-quinolone derivatives, substituted at the 3-position by a range of carbonyl-containing substitutients or by a five- or six-membered heteroaromatic moiety, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: December 12, 1995
    Assignee: Merck Sharp & Dohme Limited
    Inventors: William R. Carling, Paul D. Leeson, Michael Rowley
  • Patent number: 5472978
    Abstract: Compounds of formula (I), and salts and prodrugs thereof, wherein Q represents optionally substituted phenyl, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or indazolyl; Z represents O, S or NR.sup.8 ; X and Y are H or are together .dbd.O; R.sup.1 and R.sup.2 are H; optionally substituted C.sub.1-6 alkyl; optionally substituted phenyl(C.sub.1-4 alkyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ; R.sup.3 is H or C.sub.1-6 alkyl, R.sup.4 is H , C.sub.1-6 alkyl or optionally substituted phenyl; and R.sup.5 represents optionally substituted phenyl; are tachykinin antagonists. They and compositions thereof are useful in therapy.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: December 5, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Angus M. MacLeod, Kevin J. Merchant, Christopher J. Swain
  • Patent number: 5461063
    Abstract: Compounds of formula (I), and salts and prodrugs thereof: ##STR1## wherein X represents O or S;Y represents (CH.sub.2).sub.m, where m is 0 or 1;Z represents (CH.sub.2).sub.n, where n is 0 or 1;R.sup.1 represents optionally substituted phenyl;R.sup.2 is phenyl, naphthyl, indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl, quinolyl, benzhydryl or benzyl;R.sup.3 is H, COR.sup.a, CO.sub.2 R.sup.a C(COOR).sub.2, C(CONR.sup.a R.sup.b).sub.2, COCONR.sup.a R.sup.b, COCO.sub.2 R.sup.a, C.sub.1-6 alkyl optionally substituted by a group selected from (CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, hydroxy, cyano, COR.sup.a, NR.sup.a R.sup.b, C(NOH)NR.sup.a R.sup.b, CONHphenyl(C.sub.1-4 alkyl), COCO.sub.2 R.sup.a, C(.dbd.NR.sup.a)NR.sup.b NR.sup.c CO.sub.2 R.sup.d, CONHNR.sup.a R.sup.b, C(S)NR.sup.a R.sup.b, CONR.sup.a C.sub.1-6 alkylR.sup.12, CONR.sup.13 C.sub.2-6 alkynyl, CONR.sup.13 C.sub.2-6 alkenyl, COCONR.sup.a R.sup.b, CONR.sup.a C(NR.sup.b)NR.sup.c R.sup.d, CONR.sup.13 SO.sub.2 R.sup.a, SO.sub.2 R.sup.13 COR.sup.
    Type: Grant
    Filed: August 5, 1993
    Date of Patent: October 24, 1995
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Fintan Kelleher, Richard T. Lewis
  • Patent number: 5459270
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: October 17, 1995
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Brian Williams, Raymond Baker, Timothy Harrison, Christopher J. Swain
  • Patent number: 5451588
    Abstract: A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: September 19, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Victor G. Matassa, Leslie J. Street
  • Patent number: 5451582
    Abstract: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1.6 alkyl, or C.sub.3-7 cycloalkyl;R.sup.2 is (CH.sub.2).sub.q -tetrazolyl optionally substituted in the tetrazole ring by C.sub.1-4 alkyl, (CH.sub.2).sub.q -imidazolyl (where q is 0, 1, 2 or 3), CONHSO.sub.2 R.sup.9, SO.sub.2 NHCOR.sup.9 (where R.sup.9 is C.sub.1-6 alkyl, optionally substituted aryl or trifluoromethyl). SO.sub.2 NHR.sup.10 (where R.sup.10 is a nitrogen containing heterocycle), cyclopropyl or (CH.sub.2), CO.sub.2 H, where n is 1 or 2;R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ;R.sup.4 is C.sub.1-7 straight or branched chain alkyl; andx is 0, 1, 2 or 3;are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: September 19, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark S. Chambers, Victor G. Matassa, Stephen R. Fletcher
  • Patent number: 5444074
    Abstract: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein n is 1, 2 or 3;X represents O or S;Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms optionally substituted by oxo;R.sup.1 is phenyl optionally substituted by 1, 2 or 3 of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, --OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 R.sup.b, --CO.sub.2 R.sup.a or --CONR.sup.a R.sup.b ;R.sup.2 is phenyl, indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl, quinolyl, benzhydryl, or benzyl;R.sup.4 and R.sup.5 each independently represent H, halo, C.sub.1-6 alkyl, oxo, CH.sub.2 OR.sup.a, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b ;R.sup.8 represents an optionally substituted aromatic heterocycle; andR.sup.a and R.sup.b are H, trifluoromethyl, C.sub.1-6 alkyl or phenyl optionally substituted by C.sub.
    Type: Grant
    Filed: April 13, 1993
    Date of Patent: August 22, 1995
    Assignee: Merck Sharp & Dohme Limited
    Inventors: R. Baker, T. Ladduwahetty, E. M. Seward, C. J. Swain
  • Patent number: 5432177
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: July 11, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill
  • Patent number: 5426106
    Abstract: A class of 4-hydroxy-pyrrolo[1,2-b]pyridazin-2(1H)-one derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: March 16, 1993
    Date of Patent: June 20, 1995
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Janusz J. Kulagowski, Paul D. Leeson
  • Patent number: 5420155
    Abstract: A class of 4-hydroxy-2(1H)-pyrrolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: May 30, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
  • Patent number: 5410049
    Abstract: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1-6 alkyl, or C.sub.3-7 cyclocalkyl;R.sup.2 represents a group ##STR2## wherein X is O, S or NR.sup.8 where R.sup.8 is H or C.sub.1-4 alkyl; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ;R.sup.4 is C.sub.1-7 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-7 cycloalkylalkyl or optionally substituted aryl;n is 0, 1, 2 or 3; are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: April 25, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventor: Mark S. Chambers
  • Patent number: 5405853
    Abstract: A class of novel thiadiazoles, substituted on one of the ring carbon atoms with a non-aromatic azacyclic or azabicyclic ring system, and substituted on the other ring carbon atom with a substituent of low lipophilicity, or a hydrocarbon substituent; are potent muscarinic agonists, and have good CNS penetrability. The compounds are therefore useful in the treatment of neurological and mental illnesses, and are also of benefit in the treatment of severe painful conditions.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: April 11, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, Angus M. MacLeod, John Saunders, Kevin Merchant
  • Patent number: 5384408
    Abstract: 3(R)-[2-(6-trifluoromethylpyrazin)yl]-1-azabicyclo[2.2.2]octane and its salts, and pharmaceutical formulations thereof are useful in medicine. In particular, they are useful for the treatment of neurological and mental illnesses whose clinical manifestations are due to cholinergic deficiency, and for lowering intraocular pressure. The compound may be prepared by dehydroxylating or decarboxylating the corresponding 3-hydroxy- or carboxy-quinuclidine analogue.
    Type: Grant
    Filed: March 10, 1993
    Date of Patent: January 24, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, Victor J. Lotti, Graham A. Showell
  • Patent number: 5376748
    Abstract: A class of optionally 4-substituted 3-nitro-2-oxo-1,2,3,4-tetrahydroquinoline derivatives are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: January 7, 1993
    Date of Patent: December 27, 1994
    Assignee: Merck Sharp & Dohme Limited
    Inventors: William R. Carling, Julian D. Smith, Paul D. Leeson
  • Patent number: 5360802
    Abstract: This invention relates to benzodiazepine compounds which are useful as antagonists of cholecystokinin and gastrin.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: November 1, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Mark S. Chambers, Victor G. Matassa, Stephen R. Fletcher
  • Patent number: 5348962
    Abstract: This present invention relates to a class of 4-hydroxy-2-(1H)-quinolones which are substituted in the 3-position by an optionally substituted aryl substituent. These compounds are selective non-competitive antagonists of N-methyl-D-aspartate (NMDA) receptors.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: September 20, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Janusz J. Kulagowski, Ian M. Mawer, Paul D. Leeson, Michael Rowley
  • Patent number: 5346906
    Abstract: Pyridines, substituted by a quinuclidine and a substituent of low lipophilicity or a hydrocarbon substituent, their salts and prodrugs, and formulations thereof are useful in the treatment of neurodegenerative disorders such as dementia. The compounds can be synthesized by methods analogous to these known in the art.
    Type: Grant
    Filed: November 16, 1992
    Date of Patent: September 13, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, John Saunders, Timothy M. Willson, Janusz J. Kulagowski
  • Patent number: 5334606
    Abstract: Compounds of formula (I): ##STR1## wherein Q.sup.1 represents a phenyl group substituted by one or more halo; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl;R.sup.1 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl;R.sup.2 is phenyl(C.sub.1-4 alkyl) optionally substituted in the phenyl ring by one or more groups selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, SR.sup.b, SOR.sup.b, SO.sub.2 R.sup.b, OR.sup.b, NR.sup.b R.sup.c, NR.sup.b COR.sup.c, NR.sup.b COOR.sup.c, COOR.sup.b or CONR.sup.b R.sup.c, where R.sup.b and R.sup.c independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; andZ is O, S, NR.sup.8 or CR.sup.9 R.sup.10, where R.sup.8 represents H C.sub.1-6 alkyl, phenyl, phenyl(C.sub.1-4 alkyl), COR.sup.11, COOR.sup.11, CONR.sup.9 R.sup.10 where R.sup.11 is phenyl, phenyl(C.sub.1-4 alkyl) or C.sub.1-6 alkyl, and R.sup.9 and R.sup.10 are each H, C.sub.1-6 alkyl, phenyl or phenyl(C.sub.
    Type: Grant
    Filed: November 30, 1992
    Date of Patent: August 2, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventor: Angus M. MacLeod
  • Patent number: 5331089
    Abstract: A class of monomeric or dimeric peptides containing a specific hexa- or heptapeptide unit in either linear or cyclic form are active tachykinin antagonists and are therefore useful in disease states in which these peptides have been implicated, such as allergic conditions, inflammation, migraine, arthritis and CNS disorders.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: July 19, 1994
    Assignee: Merck Sharpe & Dohme, Ltd.
    Inventors: Neil R. Curtis, Brian J. Williams
  • Patent number: 5328927
    Abstract: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein Q.sup.1 is halo substituted phenyl; naphthyl; indolyl; benzthiophenyl; benzofuranyl; benzyl; or fluorenyl;. . is an optional covalent bond;one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y are together .dbd.0 or .dbd.NOR.sup.5 ;R.sup.1 and R.sup.2 are H; C.sub.1-6 alkyl optionally substituted by hydroxy, cyano, COR.sup.c, CO.sub.2 R.sup.c, CONR.sup.c R.sup.d, or NR.sup.c R.sup.d (where R.sup.c and R.sup.d are H, C.sub.1-6 alkyl or phenyl(C.sub.0-4 alkyl) optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo and trifluoromethyl); phenyl(C.sub.1-4 alkyl) (optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo or trifluoromethyl); COR.sup.c ; CO.sub.2 R.sup.c ; CONR.sup.c R.sup.d ; COC.sub.1-6 alkylNR.sup.c R.sup.d ; CONR.sup.c COOR.sup.d ; or SO.sub.2 R.sup.c ;R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; andR.sup.4 is phenyl optionally substituted by C.sub.1-6 alkyl, C.sub.
    Type: Grant
    Filed: February 24, 1993
    Date of Patent: July 12, 1994
    Assignee: Merck Sharpe & Dohme, Ltd.
    Inventors: Richard T. Lewis, Kevin J. Merchant, Angus M. MacLeod